

EDITORIAL

ALLERGIC INFLAMMATION AND ADIPOCYTOKINES

T.C. THEOHARIDES^{1,2}, M. MAKRIS² and D. KALOGEROMITROS²

¹Laboratory of Molecular Immunopharmacology and Drug discovery, Departments of Pharmacology and Experimental Therapeutics, Biochemistry and Internal Medicine, Tufts University School of Medicine, Boston, MA, USA; ²Allergy Clinical Research Center, Allergy Unit, 2nd Dept of Dermatology and Venereology, "Attikon" University Hospital, Medical School, University of Athens, Greece;

Received November 14, 2007 – Accepted November 30, 2007

Increasing evidence indicates that inflammation is a major component of a number of diseases with atopic diathesis (1), such as asthma, atopic dermatitis, contact dermatitis, and even psoriasis. A number of cytokines are clearly implicated in inflammatory processes; some of the most important ones are IL-1, IL-6, TNF- α , as well as the newly discovered IL-32 (2) and IL-33 (3). Chemokines such as IL-8, MCP-1 and RANTES are also involved (4), and are potent chemoattractants for mast cells, which are critical for atopic diseases (5). It is of interest that at least IL-1 (6) and IL-33 (7) can induce release of IL-6 and IL-13 from mast cells, selectively without histamine. Mast cells could, therefore, participate in both IgE and non-IgE-mediated hypersensitivity responses.

There are some clinical observations suggesting a relationship between inflammatory diseases and obesity (8). For instance, one recent epidemiological study using the Danish Twin Registry showed that the age-adjusted risk of asthma was significantly increased in obese individuals of both sexes; this correlation was higher in women for whom there was also a statistical correlation with genetic predisposition with respect to candidate genes for obesity and asthma (9). The main explanation for an association between asthma and obesity suggested so far is based on the possible action of

adipocyte-derived cytokines (e.g. IL-10) to decrease immunological tolerance by inhibiting the activity of regulatory T cells (9).

Adipocytes are well known to release hormones, such as leptin and adiponectin (10). Adipocytes were first reported by Spiegelman and colleagues to make TNF- α (11). They have since been shown to secrete a surprisingly large number of cytokines including IL-6 and TNF- α , which are important in inflammation (10, 12-13). It was also recently reported that induction of intestinal inflammation stimulated preadipocytes to release inflammatory cytokines, while exposure of human mesenteric preadipocytes to substance P increased NK-1R expression and stimulated IL-8 secretion (14). Moreover, the type of adipocyte innervation may also affect their function (15).

An alternative, but not mutually exclusive, hypothesis to explain an association between inflammation and obesity could be based on the role of mast cells. We recently showed that mast cells are located among adipocytes (Fig. 1) and can be activated by allergic and non-allergic triggers to release molecules that stimulate adipocyte cytokine production directly or indirectly (Fig. 2). Such mast cell action could only be explained if they have the ability to release mediators selectively without

Key words: allergic inflammation, adipocytokines

Mailing address: T.C Theoharides, Ph.D., M.D.
Department of Pharmacology and Experimental Therapeutics,
136 Harrison Avenue,
Tufts University School of Medicine,
02446 Boston, MA, USA
Tel: ++1 617 636 6866 - Fax: ++1 617 636 2456
e-mail: theoharis.theoharides@tufts.edu




Fig. 1. Photomicrograph of white fat stained with toluidine blue (1%, pH 2) showing metachromatic mast cells (arrows) among adipocytes (magnification = x 400).




Fig. 2. Schematic representation of the proposed interactions between mast cells, adipocytes and blood vessels in promoting inflammation.

degranulation (16). TGF- β and IL-6 released from mast cells, as well as IL-6 and IL-22 released from adipocytes, could stimulate maturation and proliferation of T17 cells, which have recently been shown to be critical in autoimmune and inflammatory processes (17). Adipocytes can also release MCP-1, which is a strong mast cell chemoattractant (18), and IL-1 which can stimulate selective mast cell secretion of IL-6 (6), suggesting that there may be a reciprocal relationship between mast cells and fat depots.

These implications are particularly important given the alarming increase in obese individuals that is reaching epidemic proportions. New therapeutic approaches may target mast cell inhibition as a way of breaking the cycle between atopy-inflammation-obesity.

ACKNOWLEDGEMENTS

Some of our research was supported by US NIAMS 2 R01 AR47652-06 to TCT. We thank Dr. Andrew Greenberg (USCDA, Boston, MA) for some of the histological images.

REFERENCES

1. **Theoharides T.C. and D. Kalogeromitros.** 2006. Mast cells in allergy and inflammation. *Annals New York Acad. Sci.* 1088:78.
2. **Conti P., P. Youinou and T.C. Theoharides.** 2007. Modulation of autoimmunity by the latest interleukins (with emphasis on IL 32). The IL-32 family of cytokines. *Autoimmun. Rev.* 6:131.
3. **Carriere V., L. Roussel, N. Ortega, D.A. Lacorre, L. Americh, L. Aguilar, G. Bouche and J.P. Girard.** 2007. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor *in vivo*. *Proc. Natl. Acad. Sci. USA* 104:282.
4. **Castellani M.L., K. Bhattacharya, M. Tagen et al.** 2007. Anti-chemokine therapy for inflammatory diseases. *Int. J. Immunopathol. Pharmacol.* 20:447.
5. **Galli S.J., S. Hakae and M. Tsai.** 2005. Mast cells in the development of adaptive immune responses. *Nat. Immunol.* 6:135.
6. **Kandere-Grzybowska K., R. Letourneau, D. Kempuraj, J. Donelan, S. Poplawski, W. Boucher, A. Athanassiou and T.C. Theoharides.** 2003. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J. Immunol.* 171:4830.
7. **Allakhverdi Z., D.E. Smith, M.R. Comeau and G. Delespesse.** 2007. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. *J. Immunol.* 179:2051.
8. **Hersoug L.G. and A. Linnenberg.** 2007. The link between the epidemics of obesity and allergic diseases: does obesity induce decreased immune tolerance? *Allergy* 62:1205.
9. **Thomsen S.F., C.S. Ulrik, K.O. Kylic, T.I. Sorensen, D. Posthuma, L.R. Skadhauge, I. Steffensen and V. Backer.** 2007. Association between obesity and asthma in a twin cohort. *Allergy* 62:1199.
10. **Greenberg A.S. and M.S. Obin.** 2006. Obesity and the role of adipose tissue in inflammation and metabolism. *A.J. Clin. Nutr.* 83:461.
11. **Hotamisligil G.S., N.S. Shargill and B.M. Spiegelman.** 1993. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science* 259:87.
12. **Hotamisligil G.S.** 2006. Inflammation and metabolic disorders. *Nature* 444:860.
13. **Gusik T.J., D. Mangalat and R. Korbut.** 2006. Adipocytokines-novel link between inflammation and vascular function? *J. Physiol. Pharmacol.* 57:505.
14. **Karagiannides I., E. Kokkotou, M. Tansky, T. Tchkonja, N. Giorgadze, M. O'Brien, S.E. Leeman, J.L. Kirkland and C. Pothoulakis.** 2006. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. *Proc. Natl. Acad. Sci. USA* 103:5207.
15. **Shi H., C.K. Song, A. Giordano, S. Cinti and T.J. Bartness.** 2005. Sensory or sympathetic white adipose tissue denervation differentially affects depot growth and cellularity. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 288:R1028.
16. **Theoharides T.C., D. Kempuraj, M. Tagen, P. Conti, and D. Kalogeromitros.** 2007. Differential release of mast cell mediators and the pathogenesis of inflammation. *Immunol. Rev.* 217:65.
17. **Schmidt-Weber C.B., M. Akdis and C.A. Akdis.** 2007. TH17 cells in the big picture of immunology.

- J. Allergy Clin. Immunol.* 120:247.
18. **Conti P., X. Pang, W. Boucher, R. Letourneau, M. Reale, R.C. Barbacane, J. Thibault and T.C. Theoharides.** 1997. Impact of Rantes and MCP-1 chemokines on *in vivo* basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. *Blood* 89:4120.